Strategies and applications for CRISPRko, RNAi and beyond – SelectScience
Posted: January 9, 2021 at 2:55 am
Watch this on-demand webinar to learn more about manipulating the genes within physiologically relevant human immune cells
In this on-demand SelectScience webinar, immunology expert Dr. Verena Brucklacher-Waldert, Horizon Discovery, shares successful strategies for the manipulation of genes within physiologically relevant human immune cells. A number of case studies are presented to highlight the techniques used in a variety of applications employed for gene interrogation, including CRISPRko, RNAi and more.
Read on for highlights from our Q&A session that followed the live webinar with Ryan Donnelly, Senior Product Manager for Gene Editing at Horizon Discovery.
RD: We've spoken to a lot of customers who do what we call orthogonal studies for hit follow-up. Say you run a CRISPR knockout screen, and you get a handful of hits back, you can then see what reagents are available, maybe via traditional RNAi methods, so siRNA or shRNA. You can then run those to see if you can replicate some of the phenotypes that you saw in your knockout screen for those specific hits. The thought is, if you see a positive correlation, you now have stronger evidence that that hit was actually real, since you've now generated a similar phenotype by targeting both DNA, with your CRISPR knockout screen, as well as the RNA with those traditional kinds of RNAi methods.
In essence, you've generated a similar phenotype by targeting two different sections of the central dogma. One of the nice things about Horizon is we have readily available reagents, all genome-wide for both CRISPR knockout, CRISPR activation, siRNA and shRNAs. So, most combinations that you would be looking at for validation, we can support.
RD: There are a few. But the first one that comes to mind is when working with primary immune cells, the availability and variability of the cell type. We can extract those cells from blood samples, but there's usually a limited amount of those types of cells that we can extract from each donor. We then need to keep in mind that there can be specific variability between donors. The complexities that come along with trying to stimulate immune cells, like T cells, also need to be considered.
Another challenge that we usually see is just in the biological differences between immune cell types. We talked a lot about proliferating cell types. Some cell types lose the ability to proliferate once they've been extracted from blood.
Lastly, is a variable that we look at routinely that also comes down to cell type: cells that are in suspension versus adherent cells. This can make screening protocols quite different, depending on whether your cell types are in suspension or if they're stuck down in the bottom of a well. Those are the three main considerations when looking to conduct screening experiments within immune cells.
RD: In principle, we usually suggest a minimum of three donors, but this is all cell type dependent. Functional assays can show a high degree of variability when using cell types such as natural killer cells. But if you shift into myeloid cells, that variability in functional assays is much more limited. Another thing to keep in mind is that donor variability is not necessarily a bad thing. By mixing donors, you spread a wider vision on things like the ethnicity of those donors, sex, age, and genetics that make up the donor pool. Since they're randomized, it will give you good insight into how a variety of donors would respond and can give you higher confidence in the performance characteristics of the target that you've identified within your screen.
RD: Controls, and multiple types of controls, are absolutely critical when doing this type of work. Without them, it's really impossible to check the efficiencies in large, arrayed screens.
At Horizon, we use multiple different types of controls, and for anybody that is taking these projects on, we would recommend a similar approach. For checking the transduction efficiency, we use a combination of both lethal controls and essential genes. This will give us a nice viability readout. In essence, the more cells that die, the higher the rate of transduction efficiency.
We also incorporate non-targeting controls, and a ROSA26 guide RNA. The non-targeting control won't cut the DNA, so incurs no DNA damage. The ROSA26 guide RNA will cut, but it cuts without a functional impact to the cell. This will give us insights into the potential for DNA damage, as well as a cutting efficiency control. Lastly, we would pick a positive control based on the cell type of interest. For example, in T cells, we target CD3, as it's consistently expressed as part of the T cell receptor complex.
By doing this, we have the ability to monitor across donors, across plates, and across replicates, to look at assay performance as a whole, with the screening experiment.
Q: How does pooled screening differ from arrayed screens? And what are the advantages?
RD: The main advantage of performing a pooled screen over an arrayed screen is really the ability to scale up and analyze the whole genome with a reasonably small amount of resources. Mining the whole genome is very important when we're looking to understand new biology without any preconceived ideas. It's really a discovery approach.
Thinking about using a pool versus an arrayed screen comes down to the biological question you're attempting to answer. If it's a simple, black and white question, such as "Do my cells survive a particular stimulus?", a pooled screen is a really nice way to go. If, however, the screen needs to assess multiple different types of outcomes that use different techniques so maybe combining FACS and HTRF assays for looking at more than one parameter, arrayed screens are what you would need to use.
Learn more about modulating gene function in primary immune cells: Watch this webinar on demand here>>
SelectScience runs 10+ webinars a month across various scientific topics, discover more of our upcoming webinars>>
See original here:
Strategies and applications for CRISPRko, RNAi and beyond - SelectScience
- Bear of the Day: CRISPR Therapeutics (CRSP) - Yahoo Finance - February 14th, 2021
- Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day - Yahoo Finance - February 14th, 2021
- CRISPR Technology Market hits at $3.94 Bn by 2028 with Thermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA Technologies (IDT) - The... - February 14th, 2021
- AbbVie and Caribou partner on CAR-T cell therapy development - BioPharma-Reporter.com - February 14th, 2021
- CRISPR Treatment Offers The Potential To Live Forever - ValueWalk - February 14th, 2021
- Australia Gene Editing Market to Garner Astonishing CAGR by 2028 with Top Key Players: CRISPR Therapeutics, Thermo Fisher Scientific, GenScript... - February 14th, 2021
- CRISPR Offers the Potential to Live Forever, But to What End? - Entrepreneur - February 11th, 2021
- Global CRISPR Gene Editing Market (2020 to 2030) - Focus on Products, Applications, End-users, Country Data and Competitive Landscape -... - February 9th, 2021
- Outlook on the CRISPR Gene Editing Global Market to 2030 - Analysis and Forecasts - GlobeNewswire - February 9th, 2021
- CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day - Yahoo Finance - February 9th, 2021
- CRISPR and CAS Gene Market Competitive Insights With Global Outlook 2020-2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas... - February 9th, 2021
- Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and... - February 1st, 2021
- Massive Growth of Gene Editing Tools Market 2021 | Size, Demand, Opportunities & Forecast To 2027 | Thermofisher Scientific, CRISPR Therapeutics,... - February 1st, 2021
- Mammoth Biosciences teams with Agilent to deliver CRISPR-based coronavirus tests - FierceBiotech - February 1st, 2021
- Inherited blindness has a new cure, thanks to CRISPR - Genetic Literacy Project - February 1st, 2021
- An Alternate Approach To Stopping Mosquitoes That Spread Zika - Using CRISPR To Make Them Resistant To Carrying It - Science 2.0 - February 1st, 2021
- CRISPR and CAS Gene Market to Score Past US$ 7603.8 Million Valuation by 2027: CMI KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - February 1st, 2021
- Diseases once thought incurable are now on the cusp of treatments. It's because of CRISPR. Here's a primer - Genetic Literacy Project - February 1st, 2021
- Experts Predict the Hottest Life Science Tech in 2021 and Beyond - The Scientist - February 1st, 2021
- Got $5,000 and 5 Years to Wait? Buy These 5 Hot Biotech Stocks Now - Motley Fool - February 1st, 2021
- Bystander Killing Could Be Key Factor in CAR-T Success in Non-Hodgkin Lymphoma - Cancer Therapy Advisor - February 1st, 2021
- Study on plant genome editing with new variant of CRISPR-Cas9 - hortidaily.com - January 27th, 2021
- Using CRISPR Genetic Technology to Catch Cancer in the Act - SciTechDaily - January 27th, 2021
- Two Gene Therapies Fix Fault in Sickle Cell Disease and -thalassemia - MD Magazine - January 27th, 2021
- Comprehensive Report on Crispr And Crispr-Associated (Cas) Genes Market 2021 | Trends, Growth Demand, Opportunities & Forecast To 2027 | Intellia... - January 27th, 2021
- Natural CRISPR's Safety Feature Could Become Genetic Dimmer Switch - Genetic Engineering & Biotechnology News - January 23rd, 2021
- CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why - Yahoo Finance - January 23rd, 2021
- The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics - Yahoo Finance - January 23rd, 2021
- Investors Who Bought CRISPR Therapeutics (NASDAQ:CRSP) Shares Three Years Ago Are Now Up 411% - Simply Wall St - January 23rd, 2021
- We may have a CRISPR cure for red blood diseases sickle cell anemia and beta thalassemia - Genetic Literacy Project - January 23rd, 2021
- The ARKG ETF: Join the Genomics Revolution - ETF Trends - January 23rd, 2021
- Gene-edited crops are now a reality but will the public be on board? - The Conversation UK - January 23rd, 2021
- 'Incredible' gene-editing result in mice inspires plans to treat premature-aging syndrome in children - Science Magazine - January 9th, 2021
- CRISPR Therapeutics Is Still Looking Strong - RealMoney - RealMoney - January 9th, 2021
- Global CRISPR Technology Market Report 2020: COVID-19 Growth and Change - Market is Expected to Recover to Reach $1.55 Billion in 2023 - Forecast to... - January 9th, 2021
- What is the Market's View on Crispr Therapeutics AG (CRSP) Stock's Price and Volume Trends - InvestorsObserver - January 9th, 2021
- 5 questions facing gene therapy in 2021 - BioPharma Dive - January 9th, 2021
- CRISPR-based strategies in infectious disease diagnosis and therapy - DocWire News - January 9th, 2021
- Plant Breeding And CRISPR Plants Market Is Expected To Reach USD 21.78 Billion By 2027 | Top Companies- Bayer AG, KWS SAAT SE & Co. KGaA, DuPont,... - January 9th, 2021
- Where Does Crispr Therapeutics AG (CRSP) Stock Fall in the Biotechnology Field? - InvestorsObserver - January 9th, 2021
- CRISPR and CAS Gene Market 2021-2028 shooting revenue at US$ 7,603.8 Million with CRISPR Therapeutics, Mirus Bio, Caribou Biosciences, Editas... - January 9th, 2021
- The 221b Foundation Establishes Coalition to Control the Spread of COVID-19 in Nepal - Business Wire - January 9th, 2021
- TRIM26 is a critical host factor for HCV replication and contributes to host tropism - Science Advances - January 9th, 2021
- Four Predictions for the Future of Food in 2021 - The Spoon - January 9th, 2021
- Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking Today - The Motley Fool - January 2nd, 2021
- Should Crispr Therapeutics AG (CRSP) be in Your Portfolio? - InvestorsObserver - January 2nd, 2021
- Can CRISPR Save Florida Citrus? - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West - January 2nd, 2021
- 2020: The year science took centre-stage - The Hindu - January 2nd, 2021
- 2020 was a tough year, but there is a silver lining - Boston Herald - January 2nd, 2021
- Pairing CRISPR with a smartphone camera, this COVID-19 test finds results in 30 minutes - FierceBiotech - December 12th, 2020
- New CRISPR-based COVID-19 test uses smartphone cameras to spot virus RNA - University of California - December 12th, 2020
- Is CRISPR Therapeutics Heading for $170? - The Motley Fool - December 12th, 2020
- Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment... - December 12th, 2020
- De-extinction: Why CRISPR gene editing might be the most revolutionary development in science ever - Genetic Literacy Project - December 12th, 2020
- How CRISPR could help us discover and treat rare cancers - ZME Science - December 12th, 2020
- ASH: CRISPR-Cas9 Gene Editing Promising in TDT, SCD - HealthDay News - December 12th, 2020
- Kevin Davies' 'Editing Humanity' explores the CRISPR revolution and the ethical dilemmas that await us - Genetic Literacy Project - December 12th, 2020
- ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more - PMLiVE - December 12th, 2020
- CiBER-seq dissects genetic networks by quantitative CRISPRi profiling of expression phenotypes - Science Magazine - December 12th, 2020
- CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference - Yahoo Finance - November 30th, 2020
- Global $6.7 Billion CRISPR Technology Market Opportunities to 2030: Cas9 And gRNA, Design Tool, Plasmid and Vector, Other Delivery System Products -... - November 30th, 2020
- CRISPR Therapeutics AG [CRSP] Revenue clocked in at $77.40 million, up 99.57% YTD: Whats Next? - The DBT News - November 30th, 2020
- Crispr And Crispr-Associated (Cas) Genes Market trends, Forecast Analysis, Key segmentation by type and application to 2026 - Cheshire Media - November 30th, 2020
- CRISPR And CRISPR-Associated (Cas) Genes Market Competitive Insights with Global Outlook 2020-2026| Caribou Biosciences, Addgene, CRISPR THERAPEUTICS... - November 30th, 2020
- CRISPR Genome Editing Market Statistics and Research Analysis Released in Latest Industry Report 2020 | Coronavirus-COVID19 Impact Analysis With Top... - November 30th, 2020
- CRISPR Genome Editing Market to Exhibit Impressive Growth of CAGR during the pe - News by aeresearch - November 30th, 2020
- Autism genes affect development of neurons and glia - Spectrum - November 30th, 2020
- CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy - Science Advances - November 20th, 2020
- Heres Why You Should Stay Invested In CRISPR Stock Despite The Recent 3x Rally - Forbes - November 20th, 2020
- CRISPR for Citrus Greening - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West - November 20th, 2020
- CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Yahoo Finance - November 20th, 2020
- Viewpoint: Farming one of the 'most inefficient industries.' The CRISPR revolution could change that - Genetic Literacy Project - November 20th, 2020
- CRISPR-edited bananas immune to killer pathogens advance toward commercialization in Africa - Genetic Literacy Project - November 20th, 2020
- CRISPR Technology Market Forecast To 2026 And COVID-19 Impact Analysis - The Think Curiouser - November 20th, 2020
- Faster, Cheaper, Easier COVID-19 Testing - Powering the New Engineer - University of Florida - November 20th, 2020
- Seeing Real-Time Biological Interactions with Graphene Transistors - Clinical OMICs News - November 20th, 2020
- Crispr Technology Market to 2026: Report on Top Company Players, Industry Insights and Overview - PRnews Leader - November 20th, 2020
- Application and Product Portfolio Analysis During the forecasted period of CRISPR Technology Market - PRnews Leader - November 20th, 2020
- CRISPR Genome Editing Market Research Report- Opportunities & Challenges With Totally Different Segments, Forecast- 2026 - The Think Curiouser - November 3rd, 2020
- Latest News 2020: CRISPR Technology Market by Coronavirus-COVID19 Impact Analysis With Top Manufacturers Analysis | Top Players: Thermo Fisher... - November 3rd, 2020